Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Anxiety Disorders, Depression, Schizophrenia, Autism, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Rett Syndrome and Spasmodic Torticollis.
Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
Bristol-Myers Squibb Co
Eisai Co Ltd
Eli Lilly and Co
Heptares Therapeutics Ltd
Johnson & Johnson
Merz Pharma GmbH & Co KgaA
Novartis AG
Richter Gedeon Nyrt
Sumitomo Dainippon Pharma Co Ltd
Toray Industries Inc
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-98776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-14242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-46778212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2814617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease
Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Addex Therapeutics Ltd, H1 2018
Pipeline by Aevi Genomic Medicine Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Eisai Co Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Heptares Therapeutics Ltd, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Merz Pharma GmbH & Co KgaA, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Richter Gedeon Nyrt, H1 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Pipeline by Toray Industries Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd..1), H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Global Cytokine Inhibitor Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
Global Microbial Growth Media Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc.
The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030.
The market for microbial growth media is essential in microbiology and biotechnology rese......
Global Protein Biochip Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 92
Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser.
The global Protein Biochip market was valued at US$ 145 million i......
Global Isothermal Nucleic Acid Amplification Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 103
Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction.
T......
Global Microfluidics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 134
According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period.
The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 122
According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
Global Cytokines Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 119
According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period.
The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
Global Western Blot Imagers Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 94
According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period.
The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
Global Procalcitonin Antibody Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 125
According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
